Pine Valley Investments Ltd Liability Co Reduces Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Pine Valley Investments Ltd Liability Co reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,942 shares of the biopharmaceutical company’s stock after selling 970 shares during the quarter. Pine Valley Investments Ltd Liability Co’s holdings in Regeneron Pharmaceuticals were worth $3,819,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Brighton Jones LLC boosted its position in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $226,000. Arrowstreet Capital Limited Partnership acquired a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $3,183,000. Gabelli Funds LLC lifted its stake in Regeneron Pharmaceuticals by 3.0% in the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after buying an additional 55 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Regeneron Pharmaceuticals by 18.8% in the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after buying an additional 5,120 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q2 results substantially exceeded expectations. Regeneron reported non-GAAP EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue rose 16.7% year over year. Growth was led by record Dupixent sales, which increased 38%, and U.S. EYLEA HD sales, which jumped 52% to $596 million. Regeneron Q2 2026 Results
• Positive Sentiment: Several analysts raised their price targets after the report. Cantor Fitzgerald lifted its target to $795 and maintained an overweight rating, while Truist raised its target to $772 and reiterated buy. These targets imply additional upside based on the referenced current price. Analyst Price Target Updates
• Neutral Sentiment: Analyst sentiment remains mixed. Morgan Stanley raised its target to $758 and RBC to $737, but both maintained equal-weight or sector-perform ratings. Wells Fargo also raised its target to $750 while keeping an equal-weight rating, suggesting limited conviction despite the earnings beat. Analyst Price Target Updates
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield is modest and is unlikely to be a major stock catalyst.
• Negative Sentiment: Multiple law firms publicized a securities class action against Regeneron and its executives. The litigation alleges investors were misled about the protocol and prospects of the Phase 3 fianlimab-Libtayo melanoma trial, which ultimately failed and was associated with an approximately $11 billion market-cap loss. The September 14, 2026 lead-plaintiff deadline and continuing legal notices could pressure sentiment and create potential financial and reputational risks. Regeneron Securities Class Action

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $762.63 on Monday. The firm has a market cap of $80.63 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 28.06 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11. The company’s 50-day simple moving average is $643.13 and its 200-day simple moving average is $711.31. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter last year, the firm earned $12.81 earnings per share. The firm’s revenue was up 16.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 2.06 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Truist Financial upped their price target on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research report on Friday. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. HSBC lowered their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Finally, Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $794.83.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.